Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy (Beijing Gao Boren Hospital)

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameAutologous CD19-BCMA Dual-Target CAR T-Cell Therapy (Beijing Gao Boren Hospital)
Drug Alias NameFIT-(BCMA+CD19)-CAR-T Cells Therapy (Beijing Gao Boren Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionAnti-CD19B-cell maturation protein modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Gao Boren Hospital Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Gao Boren Hospital Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A